Clinical study on efficacy and safety of autologous gamma/delta T cell transfer therapy after pulmonary metastasectomy of colorectal cancer

Clinical study on efficacy and safety of autologous gamma/delta T cell transfer therapy after pulmonary metastasectomy of colorectal cancer - Clinical study of gamma/delta T cell therapy after pulmonary metastasectomy of colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000854

Enrollment

Registered

2007-10-18

Start date

2007-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung metastasis of colorectal cancer

Interventions

Gannma/delta T cells are injected on day0, day7, day14, day21, day28, day35, day42, day49.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with lung metastasis of colorectal cancer: - Lesion(s) is(are) to be macroscopically completely resectable; - Life-expectancy is more than 3 months; - Performance status is 0-1; - No serious abnormality in bone marrow, liver, and renal functions.

Exclusion criteria

Exclusion criteria: Patients who have - Pulmonary fibrosis or interstitial pneumonia, or their history, or predisposition to them; - Active enteritis, autoimmune diseases, and/or infections - Double cancer; - Other serious complications; - Continuous systemic administration of steroids.

Design outcomes

Primary

Measure	Time frame
Relapse rate(1 and 2 years)	—

Secondary

Measure	Time frame
Relapse free survival Overall survival Survival rate(1 and 2 years) Response of tumor-related markers Immunological response Safety	—

Countries

Japan

Contacts

Public ContactKazuhiro Kakimi

University of Tokyo, Graduate School of Medicine Department of Immunotherapeutics

immunotherapy-admin@umin.ac.jp03-5805-3161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026